These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 18374957)

  • 1. [Poly-L-lactic-acid filling of facial lipoatrophy in HIV+ patients under tritherapy].
    Thiéry G; Coulet O; Adam S; Guyot L
    Rev Stomatol Chir Maxillofac; 2008 Apr; 109(2):103-5. PubMed ID: 18374957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
    Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C
    Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy.
    Burgess CM; Quiroga RM
    J Am Acad Dermatol; 2005 Feb; 52(2):233-9. PubMed ID: 15692467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring.
    Lam SM; Azizzadeh B; Graivier M
    Plast Reconstr Surg; 2006 Sep; 118(3 Suppl):55S-63S. PubMed ID: 16936545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly-L-lactic acid injection for HIV-associated facial lipoatrophy: treatment principles, case studies, and literature review.
    Kates LC; Fitzgerald R
    Aesthet Surg J; 2008; 28(4):397-403. PubMed ID: 19083552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semipermanent filler treatment of HIV-positive patients with facial lipoatrophy: long-term follow-up evaluating MR imaging and quality of life.
    van Rozelaar L; Kadouch JA; Duyndam DA; Nieuwkerk PT; Lutgendorff F; Karim RB
    Aesthet Surg J; 2014 Jan; 34(1):118-32. PubMed ID: 24334306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV facial lipoatrophy: causes and treatment options.
    Jones D
    Dermatol Surg; 2005 Nov; 31(11 Pt 2):1519-29; discussion 1529. PubMed ID: 16416634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly-L-lactic acid: a new dimension in soft tissue augmentation.
    Rotunda AM; Narins RS
    Dermatol Ther; 2006; 19(3):151-8. PubMed ID: 16784514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients.
    Borelli C; Kunte C; Weisenseel P; Thoma-Greber E; Korting HC; Konz B
    Skin Pharmacol Physiol; 2005; 18(6):273-8. PubMed ID: 16113597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy.
    Cattelan AM; Bauer U; Trevenzoli M; Sasset L; Campostrini S; Facchin C; Pagiaro E; Gerzeli S; Cadrobbi P; Chiarelli A
    Arch Dermatol; 2006 Mar; 142(3):329-34. PubMed ID: 16549708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy.
    Moyle GJ; Brown S; Lysakova L; Barton SE
    HIV Med; 2006 Apr; 7(3):181-5. PubMed ID: 16494632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of Sculptra: a review of clinical trial data.
    Engelhard P; Humble G; Mest D
    J Cosmet Laser Ther; 2005 Dec; 7(3-4):201-5. PubMed ID: 16414909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience.
    Mest DR; Humble G
    Dermatol Surg; 2006 Nov; 32(11):1336-45. PubMed ID: 17083585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 39-year-old man with HIV-associated lipodystrophy.
    Fuller J
    JAMA; 2008 Sep; 300(9):1056-66. PubMed ID: 18677013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poly-L-lactic acid: a perspective from my practice.
    Sadick NS
    J Cosmet Dermatol; 2008 Mar; 7(1):55-60. PubMed ID: 18254813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study.
    Mest DR; Humble GM
    Dermatol Surg; 2009 Feb; 35 Suppl 1():350-9. PubMed ID: 19207325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly-L-lactic acid for facial lipoatrophy in HIV.
    El-Beyrouty C; Huang V; Darnold CJ; Clay PG
    Ann Pharmacother; 2006 Sep; 40(9):1602-6. PubMed ID: 16912248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimizing adverse events associated with poly-L-lactic acid injection.
    Narins RS
    Dermatol Surg; 2008 Jun; 34 Suppl 1():S100-4. PubMed ID: 18547172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.
    Valantin MA; Aubron-Olivier C; Ghosn J; Laglenne E; Pauchard M; Schoen H; Bousquet R; Katz P; Costagliola D; Katlama C
    AIDS; 2003 Nov; 17(17):2471-7. PubMed ID: 14600518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The "smile-and-fill" injection technique: a dynamic approach to midface volumization.
    Wang AS; Babalola O; Jagdeo J
    J Drugs Dermatol; 2014 Mar; 13(3):288-90. PubMed ID: 24595573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.